

Date: 13 April 2022

Re: Freedom of Information Request

Ref: 115-2022

Thank you for your email dated the 1/4/22, requesting information in relation to breast cancer.

The information that you require is as follows:

Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:

- **Abemaciclib (Verzenios)+ aromatase inhibitor * 0**
- **Abemaciclib (Verzenios)+ Fulvestrant (Faslodex) 7**
- **Alpelisib (Piqray) + Fulvestrant (Faslodex) 0**
- **Atezolizumab (Tecentriq)** 3**
- **Bevacizumab (Avastin) 0**
- **Eribulin (Halaven) 5**
- **Everolimus (Afinitor) + Exemestane 0**
- **Fulvestrant (Faslodex) as a single agent 0**
- **Gemcitabine + paclitaxel 0**
- **Herceptin (Trastuzumab)+ paclitaxel 0**
- **Herceptin (Trastuzumab) as a single agent 25**
- **Lapatinib (Tyverb) 0**
- **Neratinib (Nerlynx) 1**

- **Olaparib (Lynparza) 0**
- **Palbociclib (Ibrance) + aromatase inhibitor* 0**
- **Palbociclib (Ibrance) + Fulvestrant (Faslodex) 21**
- **Pertuzumab (Perjeta) + trastuzumab + docetaxel 0**
- **Ribociclib (Kisqali) + aromatase inhibitor* 0**
- **Ribociclib (Kisqali) + Fulvestrant (Faslodex) 0**
- **Talazoparib (Talzenna) 0**
- **Trastuzumab emtansine (Kadcyla) 28**
- **Other active systemic anti-cancer therapy ****

*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole

**eg. docetaxel, vinorelbine or capecitabine as a single agent

Abemaciclib	13
AC (Doxorubicin and Cyclophosphamide)	1
Aspirin/placebo (ADD Aspirin Trial)	2
Capecitabine	32
Carboplatin	1
Carboplatin + Etoposide	1
Carboplatin + Paclitaxel	5
Denosumab	192
Docetaxel	1
Docetaxel + Phesgo	2
Doxorubicin	1
EC (Epirubicin and Cyclophosphamide)	62
Epirubicin	3
Everolimus	7
Faslodex	23
Letrozole	1
Paclitaxel	84
Paclitaxel albumin (Abraxane)	9
Paclitaxel + Pertuzumab + Trastuzumab	11
Palbociclib	104
Pembrolizumab	2
Pertuzumab	2
Pertuzumab + Trastuzumab	7
Phesgo	49
Ribociclib	5
Ribociclib + Fulvestrant	1

Trastuzumab Deruxtecan (Enhertu)	12
Vinorelbine	4
Zoladex	135
Zoledronate	314

Q2. For the above patients, how many of these received their first ever dose for each product line?

Regimen name	Patient count
Abemaciclib	2
Abemaciclib + Fulvestrant	1
Atezolizumab/Paclitaxel Albumin	1
Capecitabine	8
Carboplatin + Etoposide	1
Carboplatin + Paclitaxel	4
Denosumab	19
Docetaxel + Phesgo	1
EC (Epirubicin and Cyclophosphamide)	45
Epirubicin	2
Eribulin	2
Everolimus	5
Faslodex	1
Paclitaxel	34
Paclitaxel albumin (Abraxane)	5
Paclitaxel + Pertuzumab + Trastuzumab	4
Palbociclib	8
Palbociclib + Fulvestrant	3
Phesgo	1
Ribociclib	2
Trastuzumab (Herceptin)	2
Trastuzumab Deruxtecan (Enhertu)	3
Trastuzumab (Kadcyla®)	3
Vinorelbine	1
Zoladex	6
Zoledronate	44

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>

Kind Regards,

The Information Governance Team
Contact Email: ccf-tr.foi@nhs.net